*The information featured in this template is presented as an example, the names and scenarios are fictional.*

**Note for the record: Meeting on the Role of Antibiotic Resistance in the ability of pathogenic bacteria to cause infection**

**FINAL**

**Date: (of the final note for the record)**

**Final Number of Participating Experts:**

**Final Number of Experts with disclosed interest:**

The Control for Antimicrobial Resistance unit is hosting a meeting on the Role of Antibiotic Resistance in the ability of pathogenic bacteria to cause infection, from 24-26 June 2015. 10 experts from various areas of expertise have been invited to attend. All the experts have completed and submitted their duly completed Declaration of Interest (DOI) and Confidentiality Undertaking forms. On review of the completed DOIs, the following two experts declared interests that required further consideration and discussion with the Office of Compliance, Risk Management and Ethics (CRE):

* Professor John Doe: received private funding for a research project
* Dr Jane Sandler: received research funding and is a patent holder

Further to a meeting with CRE, the technical unit sought additional information from the two experts regarding their respective disclosed interests:

**Professor John Doe**

Professor John Doe is the Head of John Hopkins Research Unit whose focus is Antimicrobial Resistance research. In his DOI, he noted that his Research Unit received funding, 100,000 USD from a private donor. After an initial screening of the DOI and consultation with CRE, the technical unit requested further information on the private donor funding, specifically the name and background of the donor. Professor Doe advised that the funding came from Melinda Gates. This information was shared with CRE.

**Conclusion**

Upon receipt and review of the additional information, it was determined that this interest did not present a conflict in respect of the meeting and Professor Doe could participate as an expert. (The request for additional information and response has been attached to the original DOI.)

**Dr Jane Sandler**

Dr Jane Sandler, is the founder of Antimicrobials Research Group, which investigates the mechanisms of action of and resistance to antibiotics, as well as exploring the role of antibiotic resistance in the ability of pathogenic bacteria to cause infection. Dr Sandler declared that she had received a number of research grants from various funding sources; she is also a holder of an antibiotic patent. After an initial screening of her DOI and consultation with CRE, additional information was requested in respect of the research grants and the patent. Dr Sandler advised that her Group has received two grants at 150,000USD each from the Bill and Melinda Gates Foundation and the National Institute of Health, as well as one 20,000 USD grant from Merck Pharmaceuticals. In respect of the patent, Dr Sandler advised that it was for the antibacterial drug Macrolides. This drug is going to be discussed at the meeting. This information was shared with CRE.

**Conclusion**

Upon receipt and review of the additional information, it was determined that Dr Sandler has a significant interest (Merck funding and the patent) in respect of the objective of the meeting. It was thereby decided that Dr Sandler be excluded from participating in the meeting. (The request for additional information and response has been attached to the original DOI.)

**Signature:**

**Technical Officer**

**Director/Coordinator**

(Copy of the final NfR to be share with the Office of CRE)